33 results on '"Kitchener, Henry"'
Search Results
2. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
- Author
-
Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, and Leary, Alexandra
- Published
- 2018
- Full Text
- View/download PDF
3. Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.
- Author
-
Kitson, Sarah, Sivalingam, Vanitha N, Bolton, James, McVey, Rhona, Nickkho-Amiry, Mashid, Powell, Melanie E, Leary, Alexandra, Nijman, Hans W, Nout, Remi A, Bosse, Tjalling, Renehan, Andrew G, Kitchener, Henry C, Edmondson, Richard J, and Crosbie, Emma J
- Published
- 2017
- Full Text
- View/download PDF
4. Premalignant disease in the genital tract in pregnancy.
- Author
-
Owens, Gemma L and Kitchener, Henry C
- Published
- 2016
- Full Text
- View/download PDF
5. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
- Author
-
Stelloo, Ellen, Bosse, Tjalling, Nout, Remi A, MacKay, Helen J, Church, David N, Nijman, Hans W, Leary, Alexandra, Edmondson, Richard J, Powell, Melanie E, Crosbie, Emma J, Kitchener, Henry C, Mileshkin, Linda, Pollock, Pamela M, Smit, Vincent T, and Creutzberg, Carien L
- Published
- 2015
- Full Text
- View/download PDF
6. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial
- Author
-
Kitchener, Henry C., Gilham, Clare, Sargent, Alexandra, Bailey, Andrew, Albrow, Rebecca, Roberts, Christopher, Desai, Mina, Mather, Jean, Turner, Andrew, Moss, Sue, and Peto, Julian
- Subjects
- *
CERVICAL cancer diagnosis , *PAPILLOMAVIRUS disease diagnosis , *MEDICAL screening evaluation , *ANALYSIS of variance , *CANCER , *CONFIDENCE intervals , *DNA , *GENES , *PROBABILITY theory , *RESEARCH funding - Abstract
Abstract: Background: The additional sensitivity of HPV testing compared with cytology could permit extended cervical screening intervals. We wished to determine, through a further (third) round of screening in the ARTISTIC trial, the protection provided by a negative baseline HPV screen compared with that of cytology over a 6year period. Methods: Cumulative rates of CIN2 or worse (CIN2+) and CIN3 or worse (CIN3+) were correlated with baseline HPV status and cytology. HPV was detected using the Hybrid Capture 2 (Qiagen) assay for high risk types and genotyped using the Linear Array (Roche) and Papillocheck (Greiner) assays. LBC was performed using ThinPrep (Hologic). Findings: Round 3 included 8,873 women of whom 6,337 had been screened in both rounds 1 and 2 and 2,536 had not been screened since round 1. The median duration of follow-up was 72.7months. The cumulative rate of CIN2+ over three rounds was 3.88% (95%CI 3.59%, 4.17%) overall; 2.39% in round 1, 0.78% in round 2 and 0.74% in round 3. Cumulative rates by baseline status were 20.53% (95%CI 19.04%, 22.08%) for abnormal cytology, 20.12% (95%CI 18.68%, 21.61%) for HPV detection, 1.41% (95%CI 1.19%, 1.65%) for negative cytology and 0.87% (95%CI 0.70%, 1.06%) for a negative HPV test. In HPV negative women aged over 50 the cumulative rate was 0.16% (95%CI 0.07%, 0.34%). Women who were HPV positive/cytology negative at entry had a cumulative CIN2+ rate of 7.73% (95%CI 6.29%, 9.36%) over 6years, twice the overall rate. Interpretation: A negative HPV test was significantly more protective than normal cytology over three rounds. The findings of this extension of ARTISTIC suggest that the screening interval could be extended to 6years if HPV testing replaced cytology as the primary screening test. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
7. Automation-assisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial
- Author
-
Kitchener, Henry C, Blanks, Roger, Dunn, Graham, Gunn, Lionel, Desai, Mina, Albrow, Rebecca, Mather, Jean, Rana, Durgesh N, Cubie, Heather, Moore, Catherine, Legood, Rosa, Gray, Alastair, and Moss, Sue
- Subjects
- *
CYTOLOGY , *AUTOMATION , *READING , *MEDICAL screening , *DIAGNOSIS of diseases in women , *STATISTICS ,CERVIX uteri disease diagnosis - Abstract
Summary: Background: The standard for reading cervical cytology is for a cytoscreener to manually search across an entire slide for abnormal cells using a conventional microscope. Automated technology can select fields of view to assess abnormal cells, which allows targeted reading by cytoscreeners. In the Manual Assessment Versus Automated Reading In Cytology (MAVARIC) trial, we compared the accuracy of these techniques for the detection of underlying disease. Methods: For this randomised controlled trial, women aged 25–64 years undergoing primary cervical screening in Manchester, UK, were randomly assigned (1:2) to receive either manual reading only or paired reading (automation-assisted reading and manual reading), between March 1, 2006, and Feb 28, 2009. In the paired arm, two automated systems were used—the ThinPrep Imaging System and the FocalPoint GS Imaging System. General practices and community clinics were randomised to either ThinPrep or to SurePath (for the FocalPoint system) liquid-based cytology with block randomisation stratified by deprivation index. Samples were then individually randomised to manual reading only or paired reading only. Laboratory staff were unaware of the allocation of each slide and concealment was maintained until the end of the reporting process. The primary outcome was sensitivity of automation-assisted reading relative to manual reading for the detection of underlying cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in the paired arm. This trial is registered, number ISRCTN66377374. Findings: 73 266 liquid-based cytology samples were obtained from women undergoing primary cervical screening; 24 688 allocated to the manual-only arm and 48 578 to the paired-reading arm. Automation-assisted reading was 8% less sensitive than manual reading (relative sensitivity 0·92, 95% CI 0·89–0·95), which was equivalent to an absolute reduction in sensitivity of 6·3%, assuming the sensitivity of manual reading to be 79%. Specificity of automation-assisted reading relative to manual reading increased by 0·6% (1·006, 95% CI 1·005–1·007). Interpretation: The inferior sensitivity of automation-assisted reading for the detection of CIN2+, combined with an inconsequential increase in specificity, suggests that automation-assisted reading cannot be recommended for primary cervical screening. Funding: National Institute for Health Research Health Technology Assessment programme. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
8. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial
- Author
-
Kitchener, Henry C, Almonte, Maribel, Thomson, Claire, Wheeler, Paula, Sargent, Alexandra, Stoykova, Boyka, Gilham, Clare, Baysson, Helene, Roberts, Christopher, Dowie, Robin, Desai, Mina, Mather, Jean, Bailey, Andrew, Turner, Andrew, Moss, Sue, and Peto, Julian
- Subjects
- *
PAPILLOMAVIRUSES , *CYTOLOGY , *CERVICAL cancer diagnosis , *MEDICAL screening , *RANDOMIZED controlled trials , *NATIONAL health services , *HEALTH outcome assessment - Abstract
Summary: Background: Testing for human papillomavirus (HPV) DNA is reportedly more sensitive than cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN). The effectiveness of HPV testing in primary cervical screening was assessed in the ARTISTIC trial, which was done over two screening rounds approximately 3 years apart (2001–03 and 2004–07) by comparing liquid-based cytology (LBC) combined with HPV testing against LBC alone. Methods: Women aged 20–64 years who were undergoing routine screening as part of the English National Health Service Cervical Screening Programme in Greater Manchester were randomly assigned (between July, 2001, and September, 2003) in a ratio of 3:1 to either combined LBC and HPV testing in which the results were revealed and acted on, or to combined LBC and HPV testing where the HPV result was concealed from the patient and investigator. The primary outcome was the detection rate of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) in the second screening round, analysed by intention to treat. This trial is registered with the International Standard Randomised Controlled Trial Number ISRCTN25417821. Findings: There were 24 510 eligible women at entry (18 386 in the revealed group, 6124 in the concealed group). In the first round of screening 233 women (1·27%) in the revealed group had CIN3+, compared with 80 (1·31%) women in the concealed group (odds ratio [OR] 0·97, 95% CI 0·75–1·25; p>0·2). There was an unexpectedly large drop in the proportion of women with CIN3+ between the first and second rounds of screening in both groups, at 0·25% (29 of 11 676) in the revealed group and 0·47% (18 of 3866 women) in the concealed group (OR 0·53, 95% CI 0·30–0·96; p=0·042). For both rounds combined, the proportion of women with CIN3+ were 1·51% (revealed) and 1·77% (concealed) (OR 0·85, 95% CI 0·67–1·08; p>0·2). Interpretation: LBC combined with HPV testing resulted in a significantly lower detection rate of CIN3+ in the second round of screening compared with LBC screening alone, but the effect was small. Over the two screening rounds combined, co-testing did not detect a higher rate of CIN3+ or CIN2+ than LBC alone. Potential changes in screening methodology should be assessed over at least two screening rounds. Funding: National Institute of Health Research Health Technology Assessment Programme. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
9. Adjuvant chemotherapy improves survival after resection of stage 1 ovarian cancer: Abstracted from: Elit L, Chambers A, Fyles A, Covens A, Carey M, Fung MFK. Systematic review of adjuvant care for women with stage I ovarian carcinoma. Cancer 2004; 101 ...
- Author
-
Kitchener, Henry C.
- Published
- 2005
- Full Text
- View/download PDF
10. Evidence-based medicine applied to cervical cancer
- Author
-
Kitchener, Henry
- Subjects
- *
CERVICAL cancer , *CLINICAL trials - Abstract
All too frequently current healthcare is characterised by non evidence based practice, variation in practice, inadequate outcome data, inequality of access to optimal treatment and ultimately a lack of evidence base. By developing a culture of evidence based medicine some of these shortcomings could be addressed. In trying to develop a true assessment of evidence, we have to confront a huge literature, much of which does not inform clinical effectiveness which is a key underpinning of an evidence base. It is necessary to adopt methodologically sound protocols as well as a systematic approach to weighing the evidence. In general informative studies should specify the population studied, the intervention, with what it is being compared, and relevant clinical outcomes. It is clear that randomised controlled trials (RCTs) will carry most weight in terms of reducing outcome bias. The Cochrane Collaboration is an international collaboration dedicated to the science of systematic reviews and meta analysis. It functions through a process of peer review of Title of Review, Proposed Protocol, Completed Review with eventual publication in the electronic Cochrane Library. There is an active Cochrane Collaborative Review Group in Gynaecological Cancer. As far as evidence for the effective management of cervical cancer is concerned, the strongest evidence would relate to the effectiveness of concurrent chemoradiation for treating locally advanced disease compared with radiation alone. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
11. The Use of Vaccines in the Prevention and Treatment of Cervical Cancer
- Author
-
Davidson, Emma J., Kitchener, Henry C., and Stern, Peter L.
- Published
- 2002
- Full Text
- View/download PDF
12. To promote maintenance or treatment, is that the question?
- Author
-
Bookman, Michael A and Kitchener, Henry C
- Subjects
- *
POLYMERASES , *ADENOSINE diphosphate , *OVARIAN cancer treatment , *DNA repair , *PLACEBOS , *CANCER chemotherapy , *GENETIC mutation - Published
- 2017
- Full Text
- View/download PDF
13. Sentinel-node biopsy in endometrial cancer: a win–win scenario?
- Author
-
Kitchener, Henry C
- Published
- 2011
- Full Text
- View/download PDF
14. Further analysis of the ARTISTIC trial – Author's reply
- Author
-
Kitchener, Henry C and Peto, Julian
- Published
- 2009
- Full Text
- View/download PDF
15. Chapter 7: Achievements and limitations of cervical cytology screening
- Author
-
Kitchener, Henry C., Castle, Philip E., and Cox, J. Thomas
- Subjects
- *
CYTOLOGY , *CELLS , *PAPILLOMAVIRUSES , *VACCINATION - Abstract
Abstract: This chapter reviews the contribution of cervical cytology, what makes it successful, the management of screen positives and how technological advances may affect its use in the future. Cervical screening has saved hundreds of thousands of lives but has not been available to women in the poorest countries. In countries where wide coverage has been achieved and quality assurance is in place, incidence and death rates have fallen by over 50% even though cervical cytology is logistically complex. The management of high-grade cervical intraepithelial neoplasia (CIN) is very effective, but low-grade cytological abnormalities require care to avoid over-treatment. The increasing rate of human papillomavirus (HPV) testing and the prospect of prophylactic vaccination will change the way cervical cytology is used, possibly giving way to HPV testing as the primary test in secondary prevention. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
16. A long-term study of the effects of norethisterone on lipoprotein metabolism in menopausal women
- Author
-
Parish, Elizabeth, Fletcher, Colin D., Hart, David M., Kitchener, Henry, and Sharpe, Graham L.M.
- Published
- 1983
- Full Text
- View/download PDF
17. OBSTETRICS AND GYNAECOLOGY.
- Author
-
Kitchener, Henry
- Abstract
Discusses several studies in the field of obstetrics and gynaecology. Benefits of giving women a choice between repeat cytology or colposcopy for the management of mildly abnormal cervical smear; Advice for women on cervical smears; Information on hysterectomy.
- Published
- 2004
18. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy.
- Author
-
Wortman, Bastiaan G., Post, Cathalijne C.B., Powell, Melanie E., Khaw, Pearly, Fyles, Anthony, D'Amico, Romerai, Haie-Meder, Christine, Jürgenliemk-Schulz, Ina M., McCormack, Mary, Do, Viet, Katsaros, Dionyssios, Bessette, Paul, Baron, Marie Hélène, Nout, Remi A., Whitmarsh, Karen, Mileshkin, Linda, Lutgens, Ludy C.H.W., Kitchener, Henry C., Brooks, Susan, and Nijman, Hans W.
- Subjects
- *
RADIOTHERAPY , *ENDOMETRIAL cancer , *INTENSITY modulated radiotherapy , *CANCER treatment , *DIARRHEA , *COMPUTERS in medicine , *RESEARCH , *FERRANS & Powers Quality of Life Index , *RESEARCH methodology , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *QUALITY of life , *QUESTIONNAIRES - Abstract
Purpose: Radiation therapy techniques have developed from 3-dimensional conformal radiation therapy (3DCRT) to intensity modulated radiation therapy (IMRT), with better sparing of the surrounding normal tissues. The current analysis aimed to investigate whether IMRT, compared to 3DCRT, resulted in fewer adverse events (AEs) and patient-reported symptoms in the randomized PORTEC-3 trial for high-risk endometrial cancer.Methods and Materials: Data on AEs and patient-reported quality of life (QoL) of the PORTEC-3 trial were available for analysis. Physician-reported AEs were graded using Common Terminology Criteria for Adverse Events v3.0. QoL was assessed by the European Organisation for Research and Treatment of Cancer QLQC30, CX24, and OV28 questionnaires. Data were compared between 3DCRT and IMRT. A P value of ≤ .01 was considered statistically significant due to the risk of multiple testing. For QoL, combined scores 1 to 2 ("not at all" and "a little") versus 3 to 4 ("quite a bit" and "very much") were compared between the techniques.Results: Of 658 evaluable patients, 559 received 3DCRT and 99 IMRT. Median follow-up was 74.6 months. During treatment no significant differences were observed, with a trend for more grade ≥3 AEs, mostly hematologic and gastrointestinal, after 3DCRT (37.7% vs 26.3%, P = .03). During follow-up, 15.4% (vs 4%) had grade ≥2 diarrhea, and 26.1% (vs 13.1%) had grade ≥2 hematologic AEs after 3DCRT (vs IMRT) (both P < .01). Among 574 (87%) patients evaluable for QoL, 494 received 3DCRT and 80 IMRT. During treatment, 37.5% (vs 28.6%) reported diarrhea after 3DCRT (vs IMRT) (P = .125); 22.1% (versus 10.0%) bowel urgency (P = 0039), and 18.2% and 8.6% abdominal cramps (P = .058). Other QoL scores showed no differences.Conclusions: IMRT resulted in fewer grade ≥3 AEs during treatment and significantly lower rates of grade ≥2 diarrhea and hematologic AEs during follow-up. Trends toward fewer patient-reported bowel urgency and abdominal cramps were observed after IMRT compared to 3DCRT. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. Informing adolescents about human papillomavirus vaccination: What will parents allow?
- Author
-
Vallely, Lorraine A., Roberts, Stephen A., Kitchener, Henry C., and Brabin, Loretta
- Subjects
- *
PAPILLOMAVIRUSES , *VACCINATION , *CERVICAL cancer , *IMMUNIZATION of children - Abstract
Summary: With the introduction of human papillomavirus (HPV) vaccination an evidence base on effective adolescent educational interventions is urgently required. We undertook formative research to develop and evaluate a film on HPV and cervical cancer prevention for school children who will be offered HPV vaccination in the UK. The main outcome measures were the number of children allowed by parents to view the film and children''s knowledge. Our results indicated that the film''s four key messages were acceptable to parents and largely understood by adolescents but these messages will need reinforcing if the full potential of a prophylactic vaccine is to be realised. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
20. Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
- Author
-
Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P.) B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, and Goss, Geraldine
- Subjects
- *
RADIOTHERAPY , *QUALITY of life , *ENDOMETRIAL cancer , *CHEMORADIOTHERAPY , *PHYSICAL mobility , *HUMAN sexuality , *RANDOMIZED controlled trials , *ENDOMETRIAL tumors , *RESEARCH funding , *STATISTICAL sampling - Abstract
Purpose: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiation therapy versus pelvic radiation therapy alone. The present analysis was performed to compare long-term adverse events (AE) and health-related quality of life (HRQOL).Methods and Materials: In the study, 660 women with high-risk endometrial cancer were randomly assigned to receive chemoradiation therapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel) or radiation therapy alone. Toxicity was graded using Common Terminology Criteria for Adverse Events, version 3.0. HRQOL was measured using EORTC QLQ-C30 and CX24/OV28 subscales and compared with normative data. An as-treated analysis was performed.Results: Median follow-up was 74.6 months; 574 (87%) patients were evaluable for HRQOL. At 5 years, grade ≥2 AE were scored for 78 (38%) patients who had received chemoradiation therapy versus 46 (24%) who had received radiation therapy alone (P = .008). Grade 3 AE did not differ significantly between the groups (8% vs 5%, P = .18) at 5 years, and only one new late grade 4 toxicity had been reported. At 3 and 5 years, sensory neuropathy toxicity grade ≥2 persisted after chemoradiation therapy in 6% (vs 0% after radiation therapy, P < .001) and more patients reported significant tingling or numbness at HRQOL (27% vs 8%, P < .001 at 3 years; 24% vs 9%, P = .002 at 5 years). Up to 3 years, more patients who had chemoradiation therapy reported limb weakness (21% vs 5%, P < .001) and lower physical (79 vs 87, P < .001) and role functioning (78 vs 88, P < .001) scores. Both treatment groups reported similar long-term global health/quality of life scores, which were better than those of the normative population.Conclusions: This study shows a long-lasting, clinically relevant, negative impact of chemoradiation therapy on toxicity and HRQOL, most importantly persistent peripheral sensory neuropathy. Physical and role functioning impairments were seen until 3 years. These long-term data are essential for patient information and shared decision-making regarding adjuvant chemotherapy for high-risk endometrial cancer. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
21. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
- Author
-
de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie-Helene, Jürgenliemk-Schulz, Ina M, Kitchener, Henry C, Nijman, Hans W, Wilson, Godfrey, Brooks, Susan, Gribaudo, Sergio, Provencher, Diane, and Hanzen, Chantal
- Subjects
- *
ENDOMETRIAL cancer , *CHEMORADIOTHERAPY , *SURVIVAL analysis (Biometry) , *MEDICAL research , *RADIOTHERAPY - Abstract
Background: The PORTEC-3 trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy versus pelvic radiotherapy alone for women with high-risk endometrial cancer. We updated the analysis to investigate patterns of recurrence and did a post-hoc survival analysis.Methods: In the multicentre randomised phase 3 PORTEC-3 trial, women with high-risk endometrial cancer were eligible if they had International Federation of Gynaecology and Obstetrics (FIGO) 2009 stage I, endometrioid grade 3 cancer with deep myometrial invasion or lymphovascular space invasion, or both; stage II or III disease; or stage I-III disease with serous or clear cell histology; were aged 18 years and older; and had a WHO performance status of 0-2. Participants were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or chemoradiotherapy (two cycles of cisplatin 50 mg/m2 given intravenously during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2 given intravenously), by use of a biased coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage, and histological type. The co-primary endpoints were overall survival and failure-free survival. Secondary endpoints of vaginal, pelvic, and distant recurrence were analysed according to the first site of recurrence. Survival endpoints were analysed by intention-to-treat, and adjusted for stratification factors. Competing risk methods were used for failure-free survival and recurrence. We did a post-hoc analysis to analyse patterns of recurrence with 1 additional year of follow-up. The study was closed on Dec 20, 2013; follow-up is ongoing. This study is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138.Findings: Between Nov 23, 2006, and Dec 20, 2013, 686 women were enrolled, of whom 660 were eligible and evaluable (330 in the chemoradiotherapy group, and 330 in the radiotherapy-alone group). At a median follow-up of 72·6 months (IQR 59·9-85·6), 5-year overall survival was 81·4% (95% CI 77·2-85·8) with chemoradiotherapy versus 76·1% (71·6-80·9) with radiotherapy alone (adjusted hazard ratio [HR] 0·70 [95% CI 0·51-0·97], p=0·034), and 5-year failure-free survival was 76·5% (95% CI 71·5-80·7) versus 69·1% (63·8-73·8; HR 0·70 [0·52-0·94], p=0·016). Distant metastases were the first site of recurrence in most patients with a relapse, occurring in 78 of 330 women (5-year probability 21·4%; 95% CI 17·3-26·3) in the chemoradiotherapy group versus 98 of 330 (5-year probability 29·1%; 24·4-34·3) in the radiotherapy-alone group (HR 0·74 [95% CI 0·55-0·99]; p=0·047). Isolated vaginal recurrence was the first site of recurrence in one patient (0·3%; 95% CI 0·0-2·1) in both groups (HR 0·99 [95% CI 0·06-15·90]; p=0·99), and isolated pelvic recurrence was the first site of recurrence in three women (0·9% [95% CI 0·3-2·8]) in the chemoradiotherapy group versus four (0·9% [95% CI 0·3-2·8]) in the radiotherapy-alone group (HR 0·75 [95% CI 0·17-3·33]; p=0·71). At 5 years, only one grade 4 adverse event (ileus or obstruction) was reported (in the chemoradiotherapy group). At 5 years, reported grade 3 adverse events did not differ significantly between the two groups, occurring in 16 (8%) of 201 women in the chemoradiotherapy group versus ten (5%) of 187 in the radiotherapy-alone group (p=0·24). The most common grade 3 adverse event was hypertension (in four [2%] women in both groups). At 5 years, grade 2 or worse adverse events were reported in 76 (38%) of 201 women in the chemoradiotherapy group versus 43 (23%) of 187 in the radiotherapy-alone group (p=0·002). Sensory neuropathy persisted more often after chemoradiotherapy than after radiotherapy alone, with 5-year rates of grade 2 or worse neuropathy of 6% (13 of 201 women) versus 0% (0 of 187). No treatment-related deaths were reported.Interpretation: This updated analysis shows significantly improved overall survival and failure-free survival with chemoradiotherapy versus radiotherapy alone. This treatment schedule should be discussed and recommended, especially for women with stage III or serous cancers, or both, as part of shared decision making between doctors and patients. Follow-up is ongoing to evaluate long-term survival.Funding: Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council, Project Grant, Cancer Australia Grant, Italian Medicines Agency, and the Canadian Cancer Society Research Institute. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
22. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
- Author
-
de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie-Helene, Jürgenliemk-Schulz, Ina M, Kitchener, Henry C, Nijman, Hans W, Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, and Hanzen, Chantal
- Subjects
- *
CHEMORADIOTHERAPY , *RADIOTHERAPY , *ENDOMETRIAL cancer , *RANDOMIZED controlled trials , *LYMPHADENECTOMY , *ANTINEOPLASTIC agents , *CISPLATIN , *COMPARATIVE studies , *SURGICAL excision , *GYNECOLOGIC surgery , *LYMPH node surgery , *RESEARCH methodology , *MEDICAL cooperation , *PACLITAXEL , *RESEARCH , *RESEARCH funding , *STATISTICAL sampling , *TIME , *TUMOR classification , *ENDOMETRIAL tumors , *EVALUATION research , *TREATMENT effectiveness , *CARBOPLATIN , *TUMOR grading , *TUMOR treatment - Abstract
Background: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer.Methods: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138.Results: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1-73·1). 5-year overall survival was 81·8% (95% CI 77·5-86·2) with chemoradiotherapy versus 76·7% (72·1-81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54-1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3-79·9) versus 68·6% (63·1-73·4; HR 0·71, 95% CI 0·53-0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p<0·0001). Neuropathy (grade 2 or worse) persisted significantly more often after chemoradiotherapy than after radiotherapy (20 [8%] women vs one [1%] at 3 years; p<0·0001). Most deaths were due to endometrial cancer; in four patients (two in each group), the cause of death was uncertain. One death in the radiotherapy group was due to either disease progression or late treatment complications; three deaths (two in the chemoradiotherapy group and one in the radiotherapy group) were due to either intercurrent disease or late treatment-related toxicity.Interpretation: Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival. Women with high-risk endometrial cancer should be individually counselled about this combined treatment. Continued follow-up is needed to evaluate long-term survival.Funding: Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council Project Grant and Cancer Australia, L'Agenzia Italiana del Farmaco, and Canadian Cancer Society Research Institute. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
23. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
- Author
-
Wheeler, Cosette M, Skinner, S Rachel, Del Rosario-Raymundo, M Rowena, Garland, Suzanne M, Chatterjee, Archana, Lazcano-Ponce, Eduardo, Salmerón, Jorge, McNeil, Shelly, Stapleton, Jack T, Bouchard, Céline, Martens, Mark G, Money, Deborah M, Quek, Swee Chong, Romanowski, Barbara, Vallejos, Carlos S, ter Harmsel, Bram, Prilepskaya, Vera, Fong, Kah Leng, Kitchener, Henry, and Minkina, Galina
- Subjects
- *
DRUG efficacy , *MEDICATION safety , *IMMUNOGENETICS , *PAPILLOMAVIRUSES , *IMMUNOLOGICAL adjuvants , *IMMUNOMODULATORS , *CLINICAL trials , *COMPARATIVE studies , *DNA , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *HUMAN papillomavirus vaccines , *EVALUATION research , *RANDOMIZED controlled trials , *BLIND experiment , *VACCINATION , *THERAPEUTICS ,PAPILLOMAVIRUS disease prevention ,TUMOR prevention ,CERVIX uteri tumors - Abstract
Background: Although the risk of human papillomavirus (HPV) infection is greatest in young women, women older than 25 years remain at risk. We present data from the VIVIANE study of the HPV 16/18 AS04-adjuvanted vaccine in adult women after 7 years of follow-up.Methods: In this phase 3, double-blind, randomised controlled trial, healthy women older than 25 years were enrolled (age stratified: 26-35 years, 36-45 years, and ≥46 years). Up to 15% in each age stratum had a history of HPV infection or disease. Women were randomly assigned (1:1) to receive HPV 16/18 vaccine or aluminium hydroxide control, with an internet-based system. The primary endpoint was vaccine efficacy against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or greater (CIN1+) associated with HPV 16/18. We did analyses in the according-to-protocol cohort for efficacy and total vaccinated cohort. Data for the combined primary endpoint in the according-to-protocol cohort for efficacy were considered significant when the lower limit of the 96·2% CI around the point estimate was greater than 30%. For all other endpoints and cohorts, data were considered significant when the lower limit of the 96·2% CI was greater than 0%. This study is registered with ClinicalTrials.gov, number NCT00294047.Findings: The first participant was enrolled on Feb 16, 2006, and the last study visit took place on Jan 29, 2014. 4407 women were in the according-to-protocol cohort for efficacy (n=2209 vaccine, n=2198 control) and 5747 women in the total vaccinated cohort (n=2877 vaccine, n=2870 control). At month 84, in women seronegative for the corresponding HPV type in the according-to-protocol cohort for efficacy, vaccine efficacy against 6-month persistent infection or CIN1+ associated with HPV 16/18 was significant in all age groups combined (90·5%, 96·2% CI 78·6-96·5). Vaccine efficacy against HPV 16/18-related cytological abnormalities (atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion) and CIN1+ was also significant. We also noted significant cross-protective efficacy against 6-month persistent infection with HPV 31 (65·8%, 96·2% CI 24·9-85·8) and HPV 45 (70·7%, 96·2% CI 34·2-88·4). In the total vaccinated cohort, vaccine efficacy against CIN1+ irrespective of HPV was significant (22·9%, 96·2% CI 4·8-37·7). Serious adverse events related to vaccination occurred in five (0·2%) of 2877 women in the vaccine group and eight (0·3%) of 2870 women in the control group.Interpretation: In women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18 and CIN1+ irrespective of HPV type, and infection with non-vaccine types HPV 31 and HPV 45 over 7 years of follow-up.Funding: GlaxoSmithKline Biologicals SA. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
24. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
- Author
-
de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie-Helene, Kitchener, Henry C, Nijman, Hans W, Kruitwagen, Roy F, Nout, Remi A, Verhoeven-Adema, Karen W, Smit, Vincent T, Putter, Hein, and Creutzberg, Carien L
- Subjects
- *
ENDOMETRIAL cancer risk factors , *TREATMENT of endometrial cancer , *ADJUVANT treatment of cancer , *CANCER radiotherapy , *QUALITY of life , *CANCER in women , *CANCER treatment , *DIAGNOSIS of blood diseases , *GASTROINTESTINAL disease diagnosis , *DIAGNOSIS of neurological disorders , *TUMOR treatment , *ADENOCARCINOMA , *ANTINEOPLASTIC agents , *BLOOD diseases , *CANCER invasiveness , *CISPLATIN , *CLINICAL trials , *COMPARATIVE studies , *GASTROINTESTINAL diseases , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *METASTASIS , *NEUROLOGICAL disorders , *PACLITAXEL , *PROGNOSIS , *QUESTIONNAIRES , *RADIOTHERAPY , *RESEARCH , *SURVIVAL , *TUMORS , *TUMOR classification , *ENDOMETRIAL tumors , *EVALUATION research , *RANDOMIZED controlled trials , *CASE-control method , *CARBOPLATIN , *TUMOR grading - Abstract
Background: About 15% of patients with endometrial cancer have high-risk features and are at increased risk of distant metastases and endometrial cancer-related death. We designed the PORTEC-3 trial to investigate the benefit of adjuvant chemoradiotherapy compared with radiotherapy alone for women with high-risk endometrial cancer.Methods: PORTEC-3 was a multicentre, open-label, randomised, international trial. Women with high-risk endometrial cancer were randomly allocated (1:1) to radiotherapy alone (48·6 Gy) in 1·8 Gy fractions five times a week or chemoradiotherapy (two cycles concurrent cisplatin 50 mg/m(2) and four adjuvant cycles of carboplatin area under the curve [AUC] 5 and paclitaxel 175 mg/m(2)) using a biased coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The primary endpoints of the PORTEC-3 trial were overall survival and failure-free survival analysed in the intention-to-treat population. This analysis focuses on 2-year toxicity and health-related quality of life as secondary endpoints; analysis was done according to treatment received. Health-related quality of life was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) the cervix cancer module and chemotherapy and neuropathy subscales of the ovarian cancer module at baseline, after radiotherapy and at 6, 12, 24, 36, and 60 months after randomisation. Adverse events were graded with Common Terminology Criteria for Adverse Events version 3.0. The study was closed on Dec 20, 2013, after achieving complete accrual, and follow-up remains ongoing for the primary outcomes analysis. This trial is registered with ISRCTN.com, number ISRCTN14387080, and with ClinicalTrials.gov, number NCT00411138.Findings: Between Sept 15, 2006, and Dec 20, 2013, 686 women were randomly allocated in the PORTEC-3 trial. Of these, 660 met eligibility criteria, and 570 (86%) were evaluable for health-related quality of life. Median follow-up was 42·3 months (IQR 25·8-55·1). At completion of radiotherapy and at 6 months, EORTC QLQ-C30 functioning scales were significantly lower (worse functioning) and health-related quality of life symptom scores higher (worse symptoms) for the chemoradiotherapy group compared with radiotherapy alone, improving with time. At 12 and 24 months, global health or quality of life was similar between groups, whereas physical functioning scores remained slightly lower in patients who received chemoradiotherapy compared with patients who received radiotherapy alone. At 24 months, 48 (25%) of 194 patients in the chemoradiotherapy group reported severe tingling or numbness compared with 11 (6%) of 170 patients in the radiotherapy alone group (p<0·0001). Grade 2 or worse adverse events were found during treatment in 309 (94%) of 327 patients in the chemoradiotherapy group versus 145 (44%) of 326 patients in the radiotherapy alone group, and grade 3 or worse events were found in 198 (61%) of 327 patients in the chemoradiotherapy group versus 42 (13%) of 326 patients in the radiotherapy alone group (p<0·0001), with most of the grade 3 adverse events being haematological (45%). At 12 and 24 months, no significant differences in grade 3 or worse adverse events were found between groups; only grade 2 or higher sensory neuropathy adverse events persisted at 24 months (25 [10%] of 240 patients in the chemoradiotherapy group vs one [<1%] of 247 patients in the radiotherapy alone group; p<0·0001).Interpretation: Despite the increased physician and patient-reported toxicities, this schedule of adjuvant chemotherapy given during and after radiotherapy in patients with high-risk endometrial cancer is feasible, with rapid recovery after treatment, but with persistence of patient-reported sensory neurological symptoms in 25% of patients. We await the analysis of primary endpoints before final conclusions are made.Funding: Dutch Cancer Society, Cancer Research UK, National Health and Medical Research Council, Project Grant, Cancer Australia Grant, Italian Medicines Agency, and Canadian Cancer Society Research Institute. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
25. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: Influence of assay target, cut off and age.
- Author
-
Cuschieri, Kate, Cubie, Heather, Graham, Catriona, Rowan, Jennifer, Hardie, Alison, Horne, Andrew, Earle, Camille Busby, Bailey, Andrew, Crosbie, Emma J., and Kitchener, Henry
- Subjects
- *
DNA viruses , *RNA viruses , *PAPILLOMAVIRUSES , *CERVIX uteri diseases , *COLPOSCOPY , *CERVICAL intraepithelial neoplasia , *DIAGNOSIS , *THERAPEUTICS - Abstract
Abstract: Background: As HPV testing is used increasingly for cervical disease management, there is a demand to optimise the performance of HPV tests, particularly with respect to specificity. Objectives: To compare the clinical performance of an HPV DNA and a RNA based test in women with cytological abnormalities. The influence of age and assay cut off on test performance was also assessed. Study design: A prospective comparison of the Hybrid Capture 2 test (HC2) and the Aptima HPV assay (AHPV) was performed within a colposcopy setting. Clinical sensitivity and specificity were determined for the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse. Results: Both assays were >90% sensitive for the detection of CIN2+. AHPV was slightly more specific than HC2 [49.9% (46.8–53.1) vs 45.9% (42.8, 49.1), p <0.0001]. Raising HC2 cut off to 2 RLU did not improve specificity. A cut-off of 10 RLU increased specificity by approximately 10% – although this led to a reduction in sensitivity of 6.3% which equated to 24 missed cases of CIN2+. Both assays were more specific in women over 30 years of age, compared to women under 30 (p <0.001). Conclusion: Although AHPV was more specific than HC2 in the total cohort (p <0.001), we found this difference to be smaller than other studies. This could be attributed to different indications for colposcopic referral across different settings. This study also confirms the relatively poor specificity of commercial HPV assays in women under 30. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
26. Body mass index does not influence post-treatment survival in early stage endometrial cancer: Results from the MRC ASTEC trial
- Author
-
Crosbie, Emma J., Roberts, Chris, Qian, Wendi, Swart, Ann Marie, Kitchener, Henry C., and Renehan, Andrew G.
- Subjects
- *
ENDOMETRIAL cancer , *PROBABILITY theory , *BODY mass index , *RANDOMIZED controlled trials , *PROPORTIONAL hazards models - Abstract
Abstract: Body mass index (BMI) is a major risk factor for endometrial cancer incidence but its impact on post-treatment survival is unclear. We investigated the relationships of BMI (categorised using the WHO definitions) with clinico-pathological characteristics and outcome in women treated within the MRC ASTEC randomised trial, which provides data from patients who received standardised allocated treatments and therefore reduces biases. The impact of BMI on both recurrence-free survival (RFS) and overall survival (OS) was analysed using the Cox regression models. An a priori framework of evaluating potential biases was explored. From 1408 participants, there were 1070 women with determinable BMI (median=29.1kg/m2). Histological types were endometrioid (type 1) in 893 and non-endometrioid (type 2) in 146 women; the proportion of the latter decreasing with increasing BMI (8% versus 19% for obese III WHO category versus normal weight, p trend =0.003). For type 1 carcinomas, increasing BMI was associated with less aggressive histopathological features (depth of invasion, p =0.006; tumour grade, p =0.015). With a median follow-up of 34.3months, there was no influence of BMI on RFS - adjusted HRs per 5kg/m2 were 0.98 (95% CI 0.86, 1.13) and 0.95 (0.74, 1.24), for type 1 and 2 carcinomas; and no influence on OS – adjusted HRs per 5kg/m2 were 0.96 (0.81, 1.14) and 0.92 (0.70, 1.23), respectively. These findings demonstrate an important principle: that an established link between an exposure (here, obesity) and increased incident cancer risk, does not necessarily translate into an inferior outcome following treatment for that cancer. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
27. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- Author
-
Wheeler, Cosette M, Castellsagué, Xavier, Garland, Suzanne M, Szarewski, Anne, Paavonen, Jorma, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Apter, Dan, Kitchener, Henry, Teixeira, Júlio C, Skinner, S Rachel, Jaisamrarn, Unnop, Limson, Genara, Romanowski, Barbara, Aoki, Fred Y, Schwarz, Tino F, Poppe, Willy A J, Bosch, F Xavier, and Harper, Diane M
- Subjects
- *
PAPILLOMAVIRUSES , *CERVICAL cancer , *CANCER vaccines , *ONCOGENIC viruses , *CLINICAL trials , *FOLLOW-up studies (Medicine) , *COHORT analysis - Abstract
Summary: Background: We evaluated the efficacy of the human papillomavirus HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types in the end-of-study analysis after 4 years of follow-up in PATRICIA (PApilloma TRIal against Cancer In young Adults). Methods: Healthy women aged 15–25 years with no more than six lifetime sexual partners were included in PATRICIA irrespective of their baseline HPV DNA status, HPV-16 or HPV-18 serostatus, or cytology. Women were randomly assigned (1:1) to HPV-16/18 vaccine or a control hepatitis A vaccine, via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites. The study was double-blind. The primary endpoint of PATRICIA has been reported previously; the present analysis evaluates cross-protective vaccine efficacy against non-vaccine oncogenic HPV types in the end-of-study analysis. Analyses were done for three cohorts: the according-to-protocol cohort for efficacy (ATP-E; vaccine n=8067, control n=8047), total vaccinated HPV-naive cohort (TVC-naive; no evidence of infection with 14 oncogenic HPV types at baseline, approximating young adolescents before sexual debut; vaccine n=5824, control n=5820), and the total vaccinated cohort (TVC; all women who received at least one vaccine dose, approximating catch-up populations that include sexually active women; vaccine n=9319, control=9325). Vaccine efficacy was evaluated against 6-month persistent infection, cervical intraepithelial neoplasia grade 2 or greater (CIN2+) associated with 12 non-vaccine HPV types (individually or as composite endpoints), and CIN3+ associated with the composite of 12 non-vaccine HPV types. This study is registered with ClinicalTrials.gov, number NCT00122681. Findings: Consistent vaccine efficacy against persistent infection and CIN2+ (with or without HPV-16/18 co-infection) was seen across cohorts for HPV-33, HPV-31, HPV-45, and HPV-51. In the most conservative analysis of vaccine efficacy against CIN2+, where all cases co-infected with HPV-16/18 were removed, vaccine efficacy was noted for HPV-33 in all cohorts, and for HPV-31 in the ATP-E and TVC-naive. Vaccine efficacy against CIN2+ associated with the composite of 12 non-vaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), with or without HPV-16/18 co-infection, was 46·8% (95% CI 30·7–59·4) in the ATP-E, 56·2% (37·2–69·9) in the TVC-naive, and 34·2% (20·4–45·8) in the TVC. Corresponding values for CIN3+ were 73·8% (48·3–87·9), 91·4% (65·0–99·0), and 47·5% (22·8–64·8). Interpretation: Data from the end-of-study analysis of PATRICIA show cross-protective efficacy of the HPV-16/18 vaccine against four oncogenic non-vaccine HPV types—HPV-33, HPV-31, HPV-45, and HPV-51—in different trial cohorts representing diverse groups of women. Funding: GlaxoSmithKline Biologicals. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- Author
-
Lehtinen, Matti, Paavonen, Jorma, Wheeler, Cosette M, Jaisamrarn, Unnop, Garland, Suzanne M, Castellsagué, Xavier, Skinner, S Rachel, Apter, Dan, Naud, Paulo, Salmerón, Jorge, Chow, Song-Nan, Kitchener, Henry, Teixeira, Júlio C, Hedrick, James, Limson, Genara, Szarewski, Anne, Romanowski, Barbara, Aoki, Fred Y, Schwarz, Tino F, and Poppe, Willy A J
- Subjects
- *
PAPILLOMAVIRUSES , *CLINICAL trials , *HUMAN papillomavirus vaccines , *CANCER prevention , *CERVICAL cancer treatment , *CANCER vaccines , *DNA - Abstract
Summary: Background: Cervical intraepithelial neoplasia grade 2 or greater (CIN2+) is the surrogate endpoint used in licensure trials of human papillomavirus (HPV) vaccines. Vaccine efficacy against CIN3+, the immediate precursor to invasive cervical cancer, is more difficult to measure because of its lower incidence, but provides the most stringent evidence of potential cancer prevention. We report vaccine efficacy against CIN3+ and adenocarcinoma in situ (AIS) in the end-of-study analysis of PATRICIA (PApilloma TRIal against Cancer In young Adults). Methods: Healthy women aged 15–25 years with no more than six lifetime sexual partners were included in PATRICIA, irrespective of their baseline HPV DNA status, HPV-16 or HPV-18 serostatus, or cytology. Women were randomly assigned (1:1) to receive an HPV-16/18 AS04-adjuvanted vaccine or a control hepatitis A vaccine via an internet-based central randomisation system using a minimisation algorithm to account for age ranges and study sites. The patients and study investigators were masked to allocated vaccine. The primary endpoint of PATRICIA has been reported previously. In the present end-of-study analysis, we focus on CIN3+ and AIS in the populations of most clinical interest, the total vaccinated cohort (TVC) and the TVC-naive. The TVC comprised all women who received at least one vaccine dose, approximating catch-up populations and including sexually active women (vaccine n=9319; control=9325). The TVC-naive comprised women with no evidence of oncogenic HPV infection at baseline, approximating early adolescent HPV exposure (vaccine n=5824; control=5820). This study is registered with ClinicalTrials.gov, number NCT00122681. Findings: Vaccine efficacy against CIN3+ associated with HPV-16/18 was 100% (95% CI 85·5–100) in the TVC-naive and 45·7% (22·9–62·2) in the TVC. Vaccine efficacy against all CIN3+ (irrespective of HPV type in the lesion and including lesions with no HPV DNA detected) was 93·2% (78·9–98·7) in the TVC-naive and 45·6% (28·8–58·7) in the TVC. In the TVC-naive, vaccine efficacy against all CIN3+ was higher than 90% in all age groups. In the TVC, vaccine efficacy against all CIN3+ and CIN3+ associated with HPV-16/18 was highest in the 15–17 year age group and progressively decreased in the 18–20 year and 21–25 year age groups. Vaccine efficacy against all AIS was 100% (31·0–100) and 76·9% (16·0–95·8) in the TVC-naive and TVC, respectively. Serious adverse events occurred in 835 (9·0%) and 829 (8·9%) women in the vaccine and control groups, respectively; only ten events (0·1%) and five events (0·1%), respectively, were considered to be related to vaccination. Interpretation: PATRICIA end-of-study results show excellent vaccine efficacy against CIN3+ and AIS irrespective of HPV DNA in the lesion. Population-based vaccination that incorporates the HPV-16/18 vaccine and high coverage of early adolescents might have the potential to substantially reduce the incidence of cervical cancer. Funding: GlaxoSmithKline Biologicals. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
29. The Hyperemesis Impact of Symptoms Questionnaire: Development and validation of a clinical tool
- Author
-
Power, Zoe, Campbell, Malcolm, Kilcoyne, Pamela, Kitchener, Henry, and Waterman, Heather
- Subjects
- *
MORNING sickness , *QUESTIONNAIRES , *DECISION making in clinical medicine , *COMPARATIVE studies , *PSYCHOSOCIAL factors , *SYMPTOMS - Abstract
Background: The Hyperemesis Impact of Symptoms Questionnaire is a clinical tool designed to assess holistically the impact of the physical and psychosocial symptoms of hyperemesis gravidarum (HG) on individuals. Its purpose is to aid planning and implementation of tailored care for women with HG. To our knowledge no similar tool exists. Objective: To assess the validity and reliability of the HIS questionnaire. Design: As no similar tool exists, we compared the HIS with three tools that reflect its key areas: physical impact (Pregnancy Unique Quantification of Emesis – PUQE score and markers of severity of HG), psychological impact (Hospital Anxiety and Depression Score – HADS) and social impact (SF12 quality of life score). Setting: A large regional referral, women and children's hospital in the North West of England. Participants: The HIS was evaluated on 50 women admitted to hospital with HG and 50 women recruited from ante-natal clinic without severe nausea and vomiting of pregnancy and with an uncomplicated pregnancy. Results: Good criterion validity was demonstrated by strong significant correlations with all three scores (PUQE, r =0.75, p <0.001, HADS, depression r =0.76, p <0.001, and SF12, mental component r =−0.65, p <0.001). The HIS showed good internal consistency, Cronbach alpha 0.87, split half 0.80. Conclusions: There is evidence for the validity and reliability of the HIS to assess the impact of the physical and psychosocial symptoms of HG. Further research is currently underway to establish the clinical utility of the HIS questionnaire in the care of women hospitalised with HG. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
30. Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes
- Author
-
Brabin, Loretta, Roberts, Stephen A., Farzaneh, Farah, and Kitchener, Henry C.
- Subjects
- *
CANCER treatment , *PAPILLOMAVIRUSES , *PREVENTIVE medicine , *WOMEN'S health - Abstract
Abstract: The main target group for vaccination against human papillomavirus (HPV), the sexually transmitted virus that causes cervical cancer, will be young adolescents. We undertook a population-based survey to assess parental consent and potential HPV vaccine uptake in eight secondary schools using stratified randomisation according to school type and ethnicity. Our results suggest that in socially and ethnically mixed populations such as Manchester, an HPV vaccine uptake rate of 80% may be achievable if the vaccine is perceived to be safe and effective. However, most parents lack knowledge about HPV and some are concerned about sexual health issues that would arise as part of a HPV vaccine programme. It will be important to raise general awareness of the role of HPV in cervical cancer without stigmatizing the vaccine. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
31. Cervical regeneration after diathermy excision of cervical intraepithelial neoplasia as assessed by transvaginal sonography
- Author
-
Paraskevaidis, Evangelos, Bilirakis, Evripidis, Koliopoulos, George, Lolis, Evangelos D, Kalantaridou, Sofia, Paschopoulos, Minas, Plachouras, Nicholas, Malamou-Mitsi, Vasiliki, and Kitchener, Henry C
- Subjects
- *
REGENERATION (Biology) , *CERVIX uteri , *ULTRASONIC imaging , *ELECTROCOAGULATION (Medicine) , *CERVICAL intraepithelial neoplasia , *LONGITUDINAL method - Abstract
Objective: To evaluate regeneration in cervical craters following large loop excision of the transformation zone (LLETZ) and to investigate possible differential healing patterns depending on the cone's size.Study Design: A prospective study of 100 nulliparous women who underwent LLETZ. They underwent transvaginal scanning estimation of the cervical craters (diameter, depth) immediately post-operatively and at 3, 6 and 12 months. The crater dimensions of the women with the 25 largest cones were compared to those of the women with the 25 smallest cones in each of the above points of time.Results: The mean crater size of all women at 12 months was significantly smaller from the crater size immediately post-operatively. Although, there was a statistically significant difference in mean crater dimensions between the two quartile groups immediately post-operatively, no difference was found at 6 and 12 months.Conclusion: There is a healing process of the cervical crater, which is almost completed by the sixth post-treatment month. The defect remaining in the cervix is similar whether a large or small excision was performed. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
32. The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup.
- Author
-
Gaffney, David K., Suneja, Gita, Ryu, Sang Young, McCormick, Mary, Plante, Marie, Mileshkin, Linda, Jr.Small, William, Bacon, Monica, Stuart, Gavin, and Kitchener, Henry
- Subjects
- *
GYNECOLOGIC cancer , *DIAGNOSIS of cancer in female reproductive organs , *CERVICAL cancer research , *HEALTH outcome assessment , *PATIENTS , *CANCER treatment - Published
- 2015
- Full Text
- View/download PDF
33. Therapy of Human Papillomavirus-Related Disease
- Author
-
Stern, Peter L., van der Burg, Sjoerd H., Hampson, Ian N., Broker, Thomas R., Fiander, Alison, Lacey, Charles J., Kitchener, Henry C., and Einstein, Mark H.
- Subjects
- *
PAPILLOMAVIRUS diseases , *SURGICAL excision , *IMMUNE response , *PHOTOCHEMOTHERAPY , *CERVICAL intraepithelial neoplasia , *PODOPHYLLOTOXIN , *TARGETED drug delivery , *APOPTOSIS , *THERAPEUTICS - Abstract
Abstract: This chapter reviews the current treatment of chronic and neoplastic human papillomavirus (HPV)-associated conditions and the development of novel therapeutic approaches. Surgical excision of HPV-associated lower genital tract neoplasia is very successful but largely depends on secondary prevention programmes for identification of disease. Only high-risk HPV-driven chronic, pre-neoplastic lesions and some very early cancers cannot be successfully treated by surgical procedures alone. Chemoradiation therapy of cervical cancer contributes to the 66–79% cervical cancer survival at 5 years. Outlook for those patients with persistent or recurrent cervical cancer following treatment is very poor. Topical agents such as imiquimod (immune response modifier), cidofovir (inhibition of viral replication; induction apoptosis) or photodynamic therapy (direct damage of tumour and augmentation of anti-tumour immunity) have all shown some useful efficacy (∼50–60%) in treatment of high grade vulvar intraepithelial neoplasia (VIN). Provider administered treatments of genital warts include cryotherapy, trichloracetic acid, or surgical removal which has the highest primary clearance rate. Patient applied therapies include podophyllotoxin and imiquimod. Recurrence after “successful” treatment is 30–40%. Further improvements could derive from a rational combination of current therapy with new drugs targeting molecular pathways mediated by HPV in cancer. Small molecule inhibitors targeting the DNA binding activities of HPV E1/E2 or the anti-apoptotic consequences of E6/E7 oncogenes are in preclinical development. Proteasome and histone deacetylase inhibitors, which can enhance apoptosis in HPV positive tumour cells, are being tested in early clinical trials. Chronic high-risk HPV infection/neoplasia is characterised by systemic and/or local immune suppressive regulatory or escape factors. Recently two E6/E7 vaccines have shown some clinical efficacy in high grade VIN patients and this correlated with strong and broad systemic HPV-specific T cell response and modulation of key local immune factors. Treatments that can shift the balance of immune effectors locally in combination with vaccination are now being tested. This article forms part of a special supplement entitled “Comprehensive Control of HPV Infections and Related Diseases” Vaccine Volume 30, Supplement 5, 2012. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.